Zacks Investment Research upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a buy rating in a research note issued to investors on Thursday. They currently have $16.00 price target on the stock.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
Several other research analysts also recently commented on OXFD. ValuEngine raised shares of Oxford Immunotec Global from a hold rating to a buy rating in a research note on Wednesday, September 12th. BidaskClub raised shares of Oxford Immunotec Global from a sell rating to a hold rating in a research note on Thursday, October 18th. Finally, Piper Jaffray Companies reaffirmed an overweight rating on shares of Oxford Immunotec Global in a research note on Sunday, November 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Oxford Immunotec Global currently has a consensus rating of Buy and a consensus price target of $16.67.
Shares of NASDAQ OXFD traded up $0.02 during mid-day trading on Thursday, hitting $14.90. The stock had a trading volume of 106,500 shares, compared to its average volume of 104,300. Oxford Immunotec Global has a 1 year low of $10.00 and a 1 year high of $19.19. The company has a market cap of $387.25 million, a price-to-earnings ratio of -10.96 and a beta of 0.11.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The firm had revenue of $16.10 million during the quarter, compared to analysts’ expectations of $33.60 million. During the same period in the previous year, the firm earned ($0.70) earnings per share. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, equities analysts predict that Oxford Immunotec Global will post -1.09 EPS for the current year.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,000 shares of the business’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $14.91, for a total transaction of $149,100.00. Following the transaction, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 9,000 shares in the company, valued at $139,500. The disclosure for this sale can be found here. 6.61% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of OXFD. Engineers Gate Manager LP purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $188,000. Trexquant Investment LP purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $279,000. Renaissance Technologies LLC grew its position in shares of Oxford Immunotec Global by 84.7% in the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after buying an additional 9,658 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $445,000. Finally, Hound Partners LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $524,000. 90.94% of the stock is currently owned by institutional investors and hedge funds.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.